ExaWizards Inc.TSE: 4259

Notice Regarding the Start of the SAKIGAKE Consultation for a Subsidiary’s AI-powered Cognitive Function Diagnostic Support App (SaMD)

· Issued by ExaWizards Inc. via TDnet

Filed with TSE · · 2 pages · English

Summary by 6ix AI

This consultation aims to streamline the marketing approval process by obtaining prior evaluations from the Pharmaceuticals and Medical Devices Agency (PMDA). The filing indicates that the impact on consolidated financial results for the current fiscal year is minor, with no revisions to earnings forecasts.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

ExaWizards Inc. on 6ix

Story so far

Earlier from ExaWizards

Later from ExaWizards

All ExaWizards news releases